• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Inflammatory Breast Cancer Outcomes in a Contemporary Series.当代系列研究中的炎性乳腺癌结局
Anticancer Res. 2017 Sep;37(9):5057-5063. doi: 10.21873/anticanres.11922.
2
The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.术前全身治疗后残留疾病对炎性乳腺癌患者临床结局的影响。
Ann Surg Oncol. 2017 Sep;24(9):2563-2569. doi: 10.1245/s10434-017-5903-6. Epub 2017 May 30.
3
Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.根据 IV 期炎性乳腺癌的乳腺癌亚型评估转移行为和总生存情况。
Breast Cancer Res. 2019 Oct 17;21(1):113. doi: 10.1186/s13058-019-1201-5.
4
Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.激素受体和HER2定义的分子亚型的炎性乳腺癌患者的预后:一项来自监测、流行病学和最终结果(SEER)计划的基于人群的研究。
Oncotarget. 2017 Jul 25;8(30):49370-49379. doi: 10.18632/oncotarget.17217.
5
Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.基于激素受体和HER2定义的分子亚型评估炎性乳腺癌的化疗反应和生存情况:来自美国国立癌症数据库的分析
J Cancer Res Clin Oncol. 2017 Jan;143(1):161-168. doi: 10.1007/s00432-016-2281-6. Epub 2016 Oct 4.
6
Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).摩洛哥患者炎性乳腺癌的预后:来自国家肿瘤学研究所(INO)的 219 例病例的临床、分子和病理特征。
BMC Cancer. 2018 Jul 5;18(1):713. doi: 10.1186/s12885-018-4634-9.
7
Development of CNS metastases and survival in patients with inflammatory breast cancer.中枢神经系统转移的发展和炎性乳腺癌患者的生存情况。
Cancer. 2018 Jun 1;124(11):2299-2305. doi: 10.1002/cncr.31336. Epub 2018 Mar 26.
8
Modern outcomes of inflammatory breast cancer.炎性乳腺癌的现代治疗结果。
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):619-24. doi: 10.1016/j.ijrobp.2012.01.030. Epub 2012 Mar 22.
9
Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.炎性乳腺癌生物亚型对新辅助治疗反应及癌症结局的影响。
Clin Breast Cancer. 2018 Aug;18(4):e501-e506. doi: 10.1016/j.clbc.2017.10.003. Epub 2017 Oct 7.
10
Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.肿瘤基质血管内皮生长因子 A 可预测炎性乳腺癌不良预后。
BMC Cancer. 2012 Jul 19;12:298. doi: 10.1186/1471-2407-12-298.

引用本文的文献

1
Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.炎性乳腺癌患者的病理完全缓解率和总生存率:一项国家癌症数据库研究。
Ann Surg Oncol. 2024 Nov;31(12):8057-8067. doi: 10.1245/s10434-024-16026-w. Epub 2024 Aug 19.
2
Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.基于非参数随机森林分析的稳健炎性乳腺癌基因特征。
Breast Cancer Res. 2021 Sep 27;23(1):92. doi: 10.1186/s13058-021-01467-y.
3
Current Surgical Management of Inflammatory Breast Cancer.炎性乳腺癌的当前外科治疗方法。
Ann Surg Oncol. 2021 Oct;28(10):5461-5467. doi: 10.1245/s10434-021-10522-z. Epub 2021 Aug 3.

本文引用的文献

1
Inflammatory breast cancer in the Netherlands; improved survival over the last decades.荷兰的炎性乳腺癌;过去几十年生存率有所提高。
Breast Cancer Res Treat. 2017 Apr;162(2):365-374. doi: 10.1007/s10549-017-4119-6. Epub 2017 Jan 30.
2
Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.基于激素受体和HER2定义的分子亚型评估炎性乳腺癌的化疗反应和生存情况:来自美国国立癌症数据库的分析
J Cancer Res Clin Oncol. 2017 Jan;143(1):161-168. doi: 10.1007/s00432-016-2281-6. Epub 2016 Oct 4.
3
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.乳腺癌激素受体及其他因素与辅助他莫昔芬疗效的相关性:随机试验的患者水平荟萃分析。
Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.
4
Treatment adherence and outcome in women with inflammatory breast cancer: does race matter?炎性乳腺癌患者的治疗依从性和结局:种族重要吗?
Cancer. 2011 Dec 15;117(24):5485-92. doi: 10.1002/cncr.26187. Epub 2011 Jun 20.
5
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.国际炎性乳腺癌专家小组:标准化诊断和治疗的共识声明。
Ann Oncol. 2011 Mar;22(3):515-523. doi: 10.1093/annonc/mdq345. Epub 2010 Jul 5.
6
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.在紫杉烷类药物时代,采用标准分割放疗和每日皮肤贴剂治疗炎性乳腺癌患者的局部区域治疗结果。
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1105-12. doi: 10.1016/j.ijrobp.2009.06.042. Epub 2009 Oct 30.
7
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.炎性乳腺癌多模式治疗后的局部区域治疗结果
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):474-84. doi: 10.1016/j.ijrobp.2008.01.039. Epub 2008 Apr 24.
8
Trends for inflammatory breast cancer: is survival improving?炎性乳腺癌的趋势:生存率是否正在提高?
Oncologist. 2007 Aug;12(8):904-12. doi: 10.1634/theoncologist.12-8-904.
9
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.炎性乳腺癌(IBC)与复发模式:了解一种独特疾病的生物学特性
Cancer. 2007 Oct 1;110(7):1436-44. doi: 10.1002/cncr.22927.
10
A single-center experience with inflammatory breast cancer, 1985-2003.1985年至2003年炎性乳腺癌的单中心经验
Arch Surg. 2006 Jun;141(6):567-72; discussion 572-3. doi: 10.1001/archsurg.141.6.567.

当代系列研究中的炎性乳腺癌结局

Inflammatory Breast Cancer Outcomes in a Contemporary Series.

作者信息

Pan Elizabeth, Tung Lily, Ragab Omar, Morocco Elise, Wecsler Julie, Sposto Richard, Raghavendra Akshara, Chung Eugene, Lang Julie E

机构信息

Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.

Los Angeles County and University of Southern California Medical Center Department of Surgery and Norris Comprehensive Cancer Center, Division of Breast, Soft Tissue and Endocrine Surgery, University of Southern California, Los Angeles, CA, U.S.A.

出版信息

Anticancer Res. 2017 Sep;37(9):5057-5063. doi: 10.21873/anticanres.11922.

DOI:10.21873/anticanres.11922
PMID:28870934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7431193/
Abstract

BACKGROUND

Evidence on the management of inflammatory breast cancer (IBC) is limited. This study investigated factors influencing IBC treatment outcomes such as event-free survival (EFS) and overall survival (OS).

MATERIALS AND METHODS

Data were collected from 173 patients with stage III non-IBC and 17 patients with IBC diagnosed at the Keck Medical Center and Los Angeles County and University of Southern California (LAC+USC) Medical Center. Cox proportional hazard regression evaluated associations between variables significant for EFS and OS.

RESULTS

On multivariate analysis, negative estrogen receptor (ER)status [hazard ratio (HR)=1.88, 95% confidence interval (CI)=1.11-3.18, p<0.06) and lack of postoperative radiation treatment (HR=2.07, 95% CI=1.03-4.15, p<0.04) were significant for poorer EFS. High Scarff-Bloom-Richardson (SBR) score (HR=2.24, 95% CI=0.79-6.36, p<0.13) and lack of postoperative radiation treatment to the breast (HR=4.39, 95% CI=0.39-49.55, p<0.23) were associated with lower rates of OS.

CONCLUSION

The diagnosis of IBC has a significantly worse prognosis. Receipt of post-mastectomy radiation therapy was a significant predictor of better EFS and OS.

摘要

背景

关于炎性乳腺癌(IBC)治疗的证据有限。本研究调查了影响IBC治疗结果的因素,如无事件生存期(EFS)和总生存期(OS)。

材料与方法

收集了在凯克医疗中心、洛杉矶县和南加州大学(LAC+USC)医疗中心诊断出的173例III期非IBC患者和17例IBC患者的数据。Cox比例风险回归评估了对EFS和OS有显著意义的变量之间的关联。

结果

多因素分析显示,雌激素受体(ER)阴性状态[风险比(HR)=1.88,95%置信区间(CI)=1.11 - 3.18,p<0.06]和未接受术后放疗(HR=2.07,95%CI=1.03 - 4.15,p<0.04)对较差的EFS有显著影响。高斯卡夫-布鲁姆-理查森(SBR)评分(HR=2.24,95%CI=0.79 - 6.36,p<0.13)和未对乳房进行术后放疗(HR=4.39,95%CI=0.39 - 49.55,p<0.23)与较低的OS率相关。

结论

IBC的诊断预后明显更差。接受乳房切除术后放疗是EFS和OS改善的显著预测因素。